Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Non-small Cell Lung Cancer
Related studies linked through entity extraction aliases.
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE1
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- NA
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
- Status
- COMPLETED
- Phase
- PHASE3
Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- N/A
Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE4